Early detection of ovarian cancer

Biomarkers in Medicine

Volumn 2, Issue 3, 2008, Pages 291-303

  Das, Partha M ^a   Bast Jr , Robert C ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Biomarkers; Early detection; Ovarian cancer; Proteomics; Screening

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; DNA; KALLIKREIN; LYSOPHOSPHATIDIC ACID; MESOTHELIN; MICRORNA; OSTEOPONTIN; PROSTASIN;

ALGORITHM; ANTIBODY DETECTION; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DNA METHYLATION; EARLY DIAGNOSIS; FEMALE; GENE MUTATION; HEALTH CARE COST; HUMAN; MATHEMATICAL ANALYSIS; OVARIECTOMY; OVARY CANCER; PREDICTION; PREVALENCE; PROTEIN BLOOD LEVEL; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; TRANSVAGINAL ECHOGRAPHY; URINALYSIS; VALIDATION PROCESS;

EID: 48249137385     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/17520363.2.3.291     Document Type: Review

References (91)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J. Clin. 57, 43-66 (2007).
2. Ye B, Gagnon A, Mok SC: Recent technical strategies to identify diagnostic biomarkers for ovarian cancer. Expert Rev. Proteomics 4, 121-131 (2007).
3. Smith LH, Morris CR, Yasmeen S, Parikh-Patel A, Cress RD, Romano PS: Ovarian cancer: can we make the clinical diagnosis earlier? Cancer 104, 1398-1407 (2005).
4. Muto MG, Welch WR, Mok SC et al.: Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. Cancer Res. 55, 490-492 (1995).
5. Jacobs IJ, Kohler MF, Wiseman RW et al.: Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J. Natl Cancer Inst. 84, 1793-1798 (1992).
6. Mok CH, Tsao SW, Knapp RC, Fishbaugh PM, Lau CC: Unifocal origin of advanced human epithelial ovarian cancers. Cancer Res. 52, 5119-5122 (1992).
7. Skates SJ, Singer DE: Quantifying the potential benefit of CA125 screening for ovarian cancer. J. Clin. Epidemiol. 44, 365-380 (1991).
8. Colgan TJ: Challenges in the early diagnosis and staging of Fallopian-tube carcinomas associated with BRCA mutations. Int. J. Gynecol. Pathol. 22, 109-120 (2003).
9. Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B: Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am. J. Surg. Pathol. 25, 1283-1289 (2001).
10. Carcangiu ML, Peissel B, Pasini B, Spatti G, Radice P, Manoukian S: Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature. Am. J. Surg. Pathol. 30, 1222-1230 (2006).
11. Naora H: The heterogeneity of epithelial ovarian cancers: reconciling old and new paradigms. Expert Rev. Mol. Med. 9, 1-12 (2007).
12. Feeley KM, Wells M: Precursor lesions of ovarian epithelial malignancy. Histopathology 38, 87-95 (2001).
13. Bast RC: Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare. Trans. Am. Clin. Climatol. Assoc. 115, 233-248 (2004).
14. Carlson KJ, Skates SJ, Singer DE: Screening for ovarian cancer. Ann. Intern. Med. 121, 124-32 (1994).
15. Schorge JO, Muto MG, Lee SJ et al.: BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis. Cancer Res. 60, 1361-1364 (2000).
16. Hutson R, Ramsdale J, Wells M: p53 protein expression in putative precursor lesions of epithelial ovarian cancer. Histopathology 27, 367-371 (1995).
17. Lancaster JM, Dressman HK, Clarke JP et al.: Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. Int. J. Gynecol. Cancer 16, 1733-1745 (2006).
18. Badgwell D, Bast RC Jr: Early detection of ovarian cancer. Dis. Markers 23, 397-410 (2007).
19. Bourne TH, Campbell S, Reynolds KM et al.: Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. Br. Med. J. 306, 1025-1029 (1993).
20. Van Nagell JR Jr, DePriest PD, Reedy MB et al.: The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol. Oncol. 77, 350-356 (2000).
21. Sato S, Yokoyama Y, Sakamoto T, Futagami M, Saito Y: Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography. Cancer 89, 582-588 (2000).
22. Van Nagell JR Jr, Depriest PD, Ueland FR et al.: Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer 109, 1887-1896 (2007).
23. Carter JR, Lau M, Fowler JM, Carlson JW, Carson LF, Twiggs LB: Blood flow characteristics of ovarian tumors: implications for ovarian cancer screening. Am. J. Obstet. Gynecol. 172, 901-907 (1995).
24. Fleischer AC, Cullinan JA, Kepple DM, Williams LL: Conventional and color Doppler transvaginal sonography of pelvic masses: a comparison of relative histologic specificities. J. Ultrasound Med. 12, 705-712 (1993).
25. Fleischer AC, Rodgers WH, Kepple DM, Williams LL, Jones HW 3rd: Color Doppler sonography of ovarian masses: a multiparameter analysis. J. Ultrasound Med. 12, 41-48 (1993).
26. Stein SM, Laifer-Narin S, Johnson MB et al.: Differentiation of benign and malignant adnexal masses: relative value of gray-scale, color Doppler, and spectral Doppler sonography. AJR Am. J. Roentgenol. 164, 381-386 (1995).
27. Valentin L: Pattern recognition of pelvic masses by gray-scale ultrasound imaging: the contribution of Doppler ultrasound. Ultrasound Obstet. Gynecol. 14, 338-347 (1999).
28. Kurjak A, Zalud I, Alfirevic Z: Evaluation of adnexal masses with transvaginal color ultrasound. J. Ultrasound Med. 10, 295-297 (1991).
29. Valentin L, Sladkevicius P, Marsal K: Limited contribution of Doppler velocimetry to the differential diagnosis of extrauterine pelvic tumors. Obstet. Gynecol. 83, 425-433 (1994).
30. Tekay A, Jouppila P: Blood flow in benign ovarian tumors and normal ovaries during the follicular phase. Obstet. Gynecol. 86, 55-59 (1995).
31. Tailor A, Jurkovic D, Bourne TH, Collins WT, Campbell S: Sonographic prediction of malignancy in adnexal masses using an artificial neural network. Br. J. Obstet. Gynaecol. 106, 21-30 (1999).
32. Guerriero S, Alcazar JL, Ajossa S et al.: Comparison of conventional color Doppler imaging and power doppler imaging for the diagnosis of ovarian cancer: results of a European study. Gynecol. Oncol. 83, 299-304 (2001).
33. Kurjak A, Kupesic S, Anic T, Kosuta D: Three-dimensional ultrasound and power doppler improve the diagnosis of ovarian lesions. Gynecol. Oncol. 76, 28-32 (2000).
34. Cohen LS, Escobar PF, Scharm C, Glimco B, Fishman DA: Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol. Oncol. 82, 40-48 (2001).
35. Bast RC Jr: Status of tumor markers in ovarian cancer screening. J. Clin. Oncol. 21, 200-205 (2003).
36. Jacobs I, Bast RC Jr: The CA125 tumour-associated antigen: a review of the literature. Hum. Reprod. 4, 1-12 (1989).
37. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC: Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Invest. 68, 1331-1337 (1981).
38. Bast RC Jr, Klug TL, St John E et al.: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309, 883-887 (1983).
39. O'Brien TJ, Raymond LM, Bannon GA et al.: New monoclonal antibodies identify the glycoprotein carrying the CA125 epitope. Am. J. Obstet Gynecol 165, 1857-1864 (1991).
40. Zurawski VR Jr, Orjaseter H, Andersen A, Jellum E: Elevated serum CA125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int. J. Cancer 42, 677-680 (1988).
41. Bast RC Jr, Siegal FP, Runowicz C et al.: Elevation of serum CA125 prior to diagnosis of an epithelial ovarian carcinoma. Gynecol. Oncol. 22, 115-120 (1985).
42. Einhorn N, Sjovall K, Knapp RC et al.: Prospective evaluation of serum CA125 levels for early detection of ovarian cancer. Obstet. Gynecol. 80, 14-18 (1992).
43. Jacobs IJ, Skates S, Davies AP et al.: Risk of diagnosis of ovarian cancer after raised serum CA125 concentration: a prospective cohort study. Br. Med. J. 313, 1355-1358 (1996).
44. Skates SJ, Menon U, MacDonald N et al.: Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J. Clin. Oncol. 21, S206-S210 (2003).
45. Jacobs I, Stabile I, Bridges J et al.: Multimodal approach to screening for ovarian cancer. Lancet 1, 268-271 (1988).
46. Jacobs IJ, Skates SJ, MacDonald N et al.: Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 353, 1207-1210 (1999).
47. Buys SS, Partridge E, Greene MH et al.: Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am. J. Obstet. Gynecol. 193, 1630-1639 (2005).
48. Skates SJ, Xu FJ, Yu YH et al.: Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 76, 2004-2010 (1995).
49. Menon U, Skates SJ, Lewis S et al.: Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J. Clin. Oncol. 23, 7919-7926 (2005).
50. Hough CD, Sherman-Baust CA, Pizer ES et al.: Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 60, 6281-6287 (2000).
51. Hellstrom I, Raycraft J, Hayden-Ledbetter M et al.: The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 63, 3695-3700 (2003).
52. Lu KH, Patterson AP, Wang L et al.: Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin. Cancer Res. 10, 3291-3300 (2004).
53. Rosen DG, Wang L, Atkinson JN et al.: Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol. Oncol. 99, 267-277 (2005).
54. Moore RG, Brown AK, Miller MC et al.: The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol. Oncol. 108(2), 402-408 (2007).
55. Scholler N, Fu N, Yang Y et al.: Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc. Natl Acad. Sci. USA 96, 11531-11536 (1999).
56. McIntosh MW, Drescher C, Karlan B et al.: Combining CA125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol. Oncol. 95, 9-15 (2004).
57. Badgwell D, Lu Z, Cole L et al.: Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecal. Oncol. 106(3), 490-497 (2007).
58. Mok SC, Chao J, Skates S et al.: Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst. 93, 1458-1464 (2001).
59. Mills GB, Bast RC Jr, Srivastava S: Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. J. Natl Cancer Inst. 93, 1437-1439 (2001).
60. Yousef GM, Diamandis EP: Tissue kallikreins: new players in normal and abnormal cell growth? Thromb. Haemost. 90, 7-16 (2003).
61. Luo LY, Bunting P, Scorilas A, Diamandis EP: Human kallikrein 10: a novel tumor marker for ovarian carcinoma? Clin. Chim. Acta 306, 111-118 (2001).
62. Diamandis EP, Okui A, Mitsui S et al.: Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res. 62, 295-300 (2002).
63. Wong KK, Cheng RS, Mok SC: Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques 30, 670-675 (2001).
64. Kim JH, Skates SJ, Uede T et al.: Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287, 1671-1679 (2002).
65. Nakae M, Iwamoto I, Fujino T et al.: Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. J. Obstet. Gynaecol. Res. 32, 309-314 (2006).
66. Ye B, Skates S, Mok SC et al.: Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin. Cancer Res. 12, 432-441 (2006).
67. Xu Y, Fang XJ, Casey G, Mills GB: Lysophospholipids activate ovarian and breast cancer cells. Biochem. J. 309(Pt 3), 933-940 (1995).
68. Xu Y, Gaudette DC, Boynton JD et al.: Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin. Cancer Res. 1, 1223-1232 (1995).
69. Xu Y, Shen Z, Wiper DW et al.: Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280, 719-723 (1998).
70. Xu FJ, Ramakrishnan S, Daly L et al.: Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. Am. J. Obstet. Gynecol. 165, 1356-1362 (1991).
71. Xu FJ, Yu YH, Daly L et al.: OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures. J. Clin. Oncol. 11, 1506-1510 (1993).
72. Gorelik E, Landsittel DP, Marrangoni AM et al.: Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 14, 981-987 (2005).
73. Lokshin AE, Winans M, Landsittel D et al.: Circulating IL-8 and anti-IL-8 autuantibody in patients with ovarian cancer. Gynecol. Oncol. 102, 244-251 (2006).
74. Woolas RP, Conaway MR, Xu F et al.: Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Cynecol. Oncol. 59, 111-116 (1995).
75. Zhang Z, Barnhill SD, Zhang H et al.: Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol. Oncol. 73, 56-61 (1999).
76. Zhang Z, Yu Y, Xu F et al.: Combining multiple serum tumor markers improves detection of stage 1 epithelial ovarian cancer. Gynecol. Oncol. 107, 526-531 (2007).
77. Yurkovetsky ZR, Linkov FY, Malehorn D, Lokshin AE: Multiple biomarker panels for early detection of ovarian cancer. Future Oncol. 2, 733-741 (2006).
78. Lee CJ, Ariztia EV, Fishman DA: Conventional and proteomic technologies for the detection of early stage malignancies: markers for ovarian cancer. Crit. Rev. Clin. Lab. Sci. 44, 87-114 (2007).
79. Petricoin EF, Ardekani AM, Hitt BA et al.: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572-577 (2002).
80. Baggerly KA, Morris JS, Coombes KR: Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformation 20, 777-785 (2004).
81. Sorace JM, Zhan M: A data review and reassessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics 4, 24 (2003).
82. Zhang Z, Bast RC Jr, Yu Y et al.: Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64, 5882-5890 (2004).
83. Clarke CH, Yip C, Joy C et al.: Addition of a panel of seven proteomic markers to CA 125 increases sensitivity for detection of patients with stage I epithelial ovarian cancer. Presented at: 15th SPORE Invesagators' Workshop. Baltimore, MD, USA, 7-10 July 2007.
84. Iorio MV, Visone R, Di Leva G et al.: MicroRNA signatures in human ovarian cancer. Cancer Res. 67, 8699-8707 (2007).
85. Zhang L, Huang J, Yang N et al.: microRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl Acad. Sci. USA 103, 9136-9141 (2006).
86. Kopf E, Zharhary D: Antibody arrays: an emerging tool in cancer proteomics. Int. J. Biochem. Cell Biol. 39, 1305-1317 (2007).
87. Sanchez-Carbayo M, Socci ND, Lozano JJ, Haab BB, Cordon-Cardo C: Profiling bladder cancer using targeted antibody arrays. Am. J. Pathol. 168, 93-103 (2006).
88. Wiley A, Katsaros D, Fracchioli S, Yu H: Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. Int. J. Gynecol. Cancer 16, 210-218 (2006).
89. Veeck J, Niederacher D, An H et al.: Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene 25, 3479-3488 (2006).
90. Kikuchi R, Tsuda H, Kanai Y et al.: Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer. Cancer Res. 67, 7095-7105 (2007).
91. Bermudez Y, Anderson NS, Badgwell d et al.: urinary levels of bcl-2 are elevated in ovarian cancer. Proc. Am. Assoc. Cancer Res. 963 (2008).